This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $18,983,815 | $20,796,076 | $228,667 | $16,882,003 | $10,252,100 |
| FY2023 | 990 | $16,745,686 | $18,411,117 | $263,667 | $18,245,423 | $10,517,844 |
| FY2022 | 990 | $18,062,675 | $16,819,032 | $212,650 | $18,463,467 | $11,702,038 |
| FY2021 | 990 | $17,434,390 | $14,439,887 | $142,000 | $20,383,236 | $12,830,671 |
| FY2020amended | 990 | $14,864,659 | $14,507,444 | $326,667 | $17,557,878 | $9,563,499 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 100% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| CASE WESTERN RESERVE UNIVERSITYCLEVELAND, OH | NOVEL ADJUVANTS TO PROTEASOME INHIBITORS FOR MYELOMA THERAPY | $53,333 | 2023 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Yelak Biru | CEO, PRESIDENT, DIRECTOR | 40.00 | $430,000 |
| Christine Battistini | DIRECTOR | 1.00 | $0 |
| Loraine Boyle | DIRECTOR | 1.00 | $0 |
| Martine Elias | DIRECTOR |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| NEW YORK WEILL CORNELL MEDICAL CENTER FUND INCNEW YORK, NY |
| CHARACTERIZING THE ROLE AND TARGETING OF THE HISTONE METHYLTRANSFERASE SETD2 IN MULTIPLE MYELOMA. |
| $53,333 |
| 2024 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCESWINSTONSALEM, NC | LEVERAGING POLYAMINE DEPENDENCY FOR TREATMENT OF DRUG RESISTANT MULTIPLE MYELOMAS | $53,333 | 2020 |
| THE GENERAL HOSPITAL CORPORATIONBOSTON, MA | ADVANCING SPINAL STABILITY IN MULTIPLE MYELOMA: A PREDICTIVE BIOMECHANICAL SIMULATION APPROACH. | $33,333 | 2024 |
| DANA FARBER CANCER INSTITUTEBOSTON, MA | CHARACTERIZATION OF RROL-DRIVEN LIPOGENIC SIGNALING IN MULTIPLE MYELOMA CELLS | $33,333 | 2021 |
| MEMORIAL SLOAN KETTERING CANCER CENTRENEW YORK, NY | DECIPHERING THE IMPACT OF MELPHALAN ON SECONDARY MALIGNANCY IN MULTIPLE MYELOMA | $33,333 | 2020 |
| DANA FARBER CANCER INSTITUTEBOSTON, MA | DEFINING CELL STATES UNDERLYING TREATMENT RESISTANCE IN MYELOMA BY INTEGRATING MULTIOMIC SEQUENCING DATA | $33,333 | 2023 |
| TRUSTEES OF BOSTON UNIVERSITYBOSTON, MA | DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS. | $33,333 | 2024 |
| UNIVERSITY OF SAN DIEGOSAN DIEGO, CA | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | $33,333 | 2022 |
| MICHIGAN STATE UNIVERSITYEAST LANSING, MI | TARGETING C-MYC DEGRADATION TO TREAT MULTIPLE MYELOMA | $26,667 | 2020 |
| CASE WESTERN RESERVE UNIVERSITYCLEVELAND, OH | DECIPHERING THE EPIGENOMIC MECHANISMS OF TRANSFORMATION FROM BENIGN MONOCLONAL GAMMAPATHIES TO SYMPTOMATIC MULTIPLE MYELOMA. | $26,667 | 2024 |
| WAKE FOREST UNIVERSITY HEALTH SCIENCESWINSTONSALEM, NC | LEVERAGING POLYAMINE DEPENDENCY FOR TREATMENT OF DRUG RESISTANT MULTIPLE MYELOMAS | $26,666 | 2021 |
| MEMORIAL SLOAN KETTERING CANCER CENTRENEW YORK, NY | DECIPHERING THE IMPACT OF MELPHALAN ON SECONDARY MALIGNANCY IN MULTIPLE MYELOMA | $16,667 | 2021 |
| DANA FARBER CANCER INSTITUTEBOSTON, MA | OVERCOMING RESISTANCE TO PHARMACOLOGICAL DEGRADERS OF MYELOMA ONCOPROTEINS | $16,667 | 2020 |
| TRUSTEES OF BOSTON UNIVERSITYBOSTON, MA | DEFINING A MOLECULAR SIGNATURE OF CARDIOTOXICITY IN SYSTEMIC IMMUNOGLOBIN LIGHT CHAIN AMYLOIDOSIS | $16,667 | 2023 |
| DANA FARBER CANCER INSTITUTEBOSTON, MA | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | $16,667 | 2024 |
| DANA FARBER CANCER INSTITUTEBOSTON, MA | CHARACTERIZATION OF RROL-DRIVEN LIPOGENIC SIGNALING IN MULTIPLE MYELOMA CELLS. | $16,667 | 2022 |
| UNIVERSITY OF SAN DIEGOSAN DIEGO, CA | TUNING THE INNATE IMMUNE MULTIPLE MYELOMA MICROENVIRONMENT BY MODULATING IRF4 | $16,667 | 2023 |
| 1.00 |
| $0 |
| George T Hayum | DIRECTOR | 1.00 | $0 |
| Jason Katz | DIRECTOR | 1.00 | $0 |
| Benson Klein | DIRECTOR | 1.00 | $0 |
| Andrew Kuzneski Iii | DIRECTOR | 1.00 | $0 |
| Dr Heinz Ludwig | DIRECTOR | 1.00 | $0 |
| Charles Newman | DIRECTOR | 1.00 | $0 |
| Matthew Robinson | DIRECTOR | 1.00 | $0 |
| Dr Vincent Rajkumar | CHAIRMAN | 40.00 | $0 |
| E Michael Scott | DIRECTOR | 1.00 | $0 |
| Sanjay Singh | DIRECTOR | 1.00 | $0 |
| John O'Dwyer | DIRECTOR | 1.00 | $0 |
| Poornima Parameswaran | DIRECTOR | 1.00 | $0 |
| Jennifer Scarne | CHIEF FINANCIAL OFFICER | 40.00 | $303,088 |
| Peter Anton | VICE PRESIDENT, MARKETING | 40.00 | $225,894 |
| Robin Tuohy | VICE PRESIDENT, PATIENT SUPPORT | 40.00 | $179,562 |
| Susan Durie | DIRECTOR OF GLOBAL PATIENT EMPOWERMENT-FORMER DIR | 40.00 | $362,646 |
| Dr Brian Durie | CHIEF SCIENTIFIC OFFICER-FORMER DIR | 40.00 | $430,000 |
| Diane Moran | SENIOR VICE PRESIDENT - BUSINESS RELATIONSHIP MANA | 40.00 | $432,784 |
| Lisa Paik | EXECUTIVE VICE PRESIDENT - RESEARCH & OPERATIONS | 40.00 | $275,225 |
| Joseph Mikhael | CHIEF MEDICAL OFFICER | 40.00 | $459,562 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Sep 30, 2024IRS bulk XML
Filing id 202511539349301151
Form 990 · FY2023 · period ending Sep 30, 2023IRS bulk XML
Filing id 202442079349300024
Form 990 · FY2022 · period ending Sep 30, 2022
Filing id 202321529349300742
Form 990 · FY2021 · period ending Sep 30, 2021
Filing id 202202249349302825
Form 990 · FY2020 · period ending Sep 30, 2020 · amended
Filing id 202223219349301322
Form 990 · FY2019 · period ending Sep 30, 2019
Filing id 202011339349303416
Form 990 · FY2018 · period ending Sep 30, 2018
Filing id 201931339349307183
Form 990 · FY2017 · period ending Sep 30, 2017
Filing id 201811239349301981
Form 990 · FY2016 · period ending Sep 30, 2016
Filing id 201721309349302512
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.